RADT-07. CLINICAL RESULTS, ACUTE AND EARLY LATE TOXICITY AFTER PROTON RADIOTHERAPY FOR PEDIATRIC MEDULLOBLASTOMA, RETROSPECTIVE ANALYSIS
Rattachement africain : cz, sk, hr, bg. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Craniospinal irradiation with boost to primary tumor site (and metastatic sites) is current radiotherapy standard for most patients diagnosed with medulloblastoma (MB). This treatment is effective, but survivors frequently develop long-term toxicity affecting the quality of life. Proton radiotherapy has the same efficacy compared to conventional photon-based techiques, but might achieve lower risk of toxicity. We retrospectivelly analyzed our cohort of patients irradiated for MB in our institution, using IMPT (intensity modulated proton therapy). Between May 2013 and December 2023 eighty patients (50 male, 30 female, median age at radiotherapy 8 years/range 3-17/) with primary or recurrent MB (not previously irradiated) were treated and included into analysis. 36 patients were treated for high-risk MB (mostly metastatic), 44 pts for SR disease. Neoadjuvant, concurrent and adjuvant systemic treatment was applied according to the protocol selected by the pediatric oncologist. All but one patients completed their treatment, acute toxicity including hematological was mild and lead to treatment interruption in seven cases. With a median of follow-up 39,6 months (range 3-119) 62 pts were in complete remission, 3 pts alive with disease, 14 died from disease progression and one died from complication (intracranial hemorrhage). We were able to identify two secondary malignancies potentially associated with IMPT (thyroid cancer, radiation induced high-grade glioma). Most common endocrinopathy observed in our patients was hypothyroidism and growth-hormon decifit. Due to lack of data, we were not able to analyze cognitive functions and quality of life. There was one case of severe brainstem necrosis with persistent neurological deficit, treated with corticosteroids and bevacizumab. Proton radiotherapy using IMPT for craniospinal irradiation in MB is feasible, treatment outcomes and toxicity are encouraging, although a longer follow-up is needed.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- RADT-07. CLINICAL RESULTS, ACUTE AND EARLY LATE TOXICITY AFTER PROTON RADIOTHERAPY FOR PEDIATRIC MEDULLOBLASTOMA, RETROSPECTIVE ANALYSIS
- Date Crossref
- 18/06/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Proton Therapy Centre pays non établi dans la noticeÉtablissement de santé
-
University Hospital in Motol pays non établi dans la noticeÉtablissement de santé
-
University Hospital Bratislava pays non établi dans la noticeÉtablissement de santé
-
Comenius University Bratislava pays non établi dans la noticeUniversité ou école supérieure
-
Children's Hospital Zagreb pays non établi dans la noticeÉtablissement de santé
-
University Hospital Brno pays non établi dans la noticeÉtablissement de santé
-
Queen Giovanna Hospital pays non établi dans la noticeÉtablissement de santé
-
Proton Therapy Center Czech pays non établi dans la noticeInstitution
-
University Hospital Motol pays non établi dans la noticeUniversité ou école supérieure
-
Pediatric University Hospital pays non établi dans la noticeUniversité ou école supérieure
-
Childrens hospital pays non établi dans la noticeÉtablissement de santé
-
UMHAT ‘Tsaritsa Yoanna-ISUL pays non établi dans la noticeInstitution
Proton Therapy Centre, University Hospital in Motol et University Hospital Bratislava, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.